Loading...

Stoke Therapeutics

Nasdaq:STOK
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
STOK
Nasdaq
$766M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. The last earnings update was 60 days ago. More info.


Add to Portfolio Compare Print
STOK Share Price and Events
7 Day Returns
-10.6%
NasdaqGS:STOK
-1%
US Biotechs
-1.2%
US Market
1 Year Returns
-
NasdaqGS:STOK
-11.9%
US Biotechs
3.3%
US Market
STOK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Stoke Therapeutics (STOK) -10.6% -14.1% - - - -
US Biotechs -1% -3.6% -0.7% -11.9% 5.4% 7.4%
US Market -1.2% 0.8% 0.9% 3.3% 35.9% 41.7%
1 Year Return vs Industry and Market
  • No trading data on STOK.
  • No trading data on STOK.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

STOK Value

 Is Stoke Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Stoke Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $23.45.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Stoke Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Stoke Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:STOK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-21.92
NasdaqGS:STOK Share Price ** NasdaqGS (2019-07-19) in USD $23.45
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.44x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.86x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Stoke Therapeutics.

NasdaqGS:STOK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:STOK Share Price ÷ EPS (both in USD)

= 23.45 ÷ -21.92

-1.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stoke Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Stoke Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Stoke Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGS:STOK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.07x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-24.6%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 0.79x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Stoke Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Stoke Therapeutics's assets?
Raw Data
NasdaqGS:STOK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $111.61
NasdaqGS:STOK Share Price * NasdaqGS (2019-07-19) in USD $23.45
United States of America Biotechs Industry PB Ratio Median Figure of 437 Publicly-Listed Biotechs Companies 2.93x
United States of America Market PB Ratio Median Figure of 5,248 Publicly-Listed Companies 1.79x
NasdaqGS:STOK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:STOK Share Price ÷ Book Value per Share (both in USD)

= 23.45 ÷ 111.61

0.21x

* Primary Listing of Stoke Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stoke Therapeutics is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Stoke Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Stoke Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

STOK Future Performance

 How is Stoke Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-24.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Stoke Therapeutics expected to grow at an attractive rate?
  • Unable to compare Stoke Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Stoke Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Stoke Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:STOK Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:STOK Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -24.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:STOK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:STOK Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 0 -85 -85 2
2022-12-31 0 -61 -69 2
2021-12-31 0 -46 -53 2
2020-12-31 0 -43 -49 4
2019-12-31 0 -29 -33 4
NasdaqGS:STOK Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -16 -16
2018-12-31 -11 -13
2017-12-31 -5 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Stoke Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Stoke Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:STOK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Stoke Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:STOK Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.03 -1.50 -2.56 2.00
2022-12-31 -1.75 -1.57 -1.92 2.00
2021-12-31 -1.40 -1.29 -1.59 3.00
2020-12-31 -1.49 -1.27 -1.75 4.00
2019-12-31 -1.62 -1.20 -1.93 4.00
NasdaqGS:STOK Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -21.92
2018-12-31 -17.66
2017-12-31 -8.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Stoke Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Stoke Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Stoke Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

STOK Past Performance

  How has Stoke Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Stoke Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Stoke Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Stoke Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Stoke Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Stoke Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Stoke Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:STOK Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -16.35 5.94 11.25
2018-12-31 -12.52 4.41 8.37
2017-12-31 -5.56 1.96 3.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Stoke Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Stoke Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Stoke Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Stoke Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Stoke Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

STOK Health

 How is Stoke Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Stoke Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Stoke Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Stoke Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Stoke Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Stoke Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Stoke Therapeutics Company Filings, last reported 3 months ago.

NasdaqGS:STOK Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 99.58 0.00 98.65
2018-12-31 105.07 0.00 105.40
2017-12-31 -1.29 0.00 1.80
  • Stoke Therapeutics has no debt.
  • Stoke Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Stoke Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Stoke Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 72% each year.
X
Financial health checks
We assess Stoke Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Stoke Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

STOK Dividends

 What is Stoke Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Stoke Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Stoke Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Stoke Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Stoke Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:STOK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 18 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:STOK Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Stoke Therapeutics has not reported any payouts.
  • Unable to verify if Stoke Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Stoke Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Stoke Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Stoke Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Stoke Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Stoke Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Stoke Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

STOK Management

 What is the CEO of Stoke Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ed Kaye
AGE 70
TENURE AS CEO 1.8 years
CEO Bio

Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. Dr. Kaye serves as the Chief Executive Officer and Director of Stoke Therapeutics, Inc. since October 2017. Dr. Kaye serves as a Neurological Consultant of Children's Hospital of Boston. He served as the Chief Executive Officer and President of Sarepta Therapeutics, Inc. since September 20, 2016 until June 28, 2017 and served as its Chief Medical Officer from June 20, 2011 to March 2017. He has specific experience with pediatric neuromuscular conditions. He served as the Interim Chief Executive Officer of Sarepta Therapeutics, Inc. from March 31, 2015 to September 20, 2016 and served as its Senior Vice President from June 20, 2011 to September 20, 2016. Dr. Kaye joined Sarepta from Genzyme Corporation, where he served as Group Vice President of Clinical Development and Therapeutic Head for Lysosomal Storage Disorders and Neurodegenerative Diseases since 2007. He served leadership roles at Genzyme in Clinical Development and Medical Affairs for over 10 years, helping build an industry-leading company in rare genetic diseases. He played a leadership role in gaining Myozyme's approval for Pompe Disease and he oversaw all of Genzyme's collaborations in this field, including the development of ataluren for Duchenne Muscular Dystrophy (DMD). Prior to joining Genzyme in 2001 as Vice President of Clinical Research, Dr. Kaye served as the Chief of Biochemical Genetics at Children's Hospital of Philadelphia. Prior to this, he served as Chief of Pediatric Neurology and Director of the Barnett Mitochondrial Laboratory at St. Christopher's Hospital for Children in Philadelphia. He served as Section Head of Neurometabolism, Pediatric Neurology at The Floating Hospital for Children at Tufts University. He serves on the editorial boards of a number of journals, including Journal of Child Neurology and Pediatric Neurology. He has been Independent Director of Neurovia, Inc. since September 28, 2017. He has been Director of Cytokinetics, Incorporated since May 18, 2016. He served as a Director of Sarepta Therapeutics, Inc. since September 20, 2016 until June 28, 2017. He served as a Member of Scientific Advisory Board at Lumos Pharma, Inc. Dr. Kaye is a Member of several scientific advisory boards, including the CureDuchenne, United Leukodystrophy Foundation, Prize4Life, CureCMD (Congenital Muscular Dystrophy) and Spinal Muscular Atrophy Foundation advisory boards. He served on the board of Annals of Neurology. He was Research Fellow in gene therapy at Massachusetts General Hospital. He was Associate Professor of Neurology and Pediatrics at University of Pennsylvania School of Medicine. Dr. Kaye received his medical education and pediatric training at Loyola University Stritch School of Medicine and University Hospital and child neurology training at Boston City Hospital, Boston University and completed his training as a Neurochemical Research Fellow at Bedford VA Hospital, Boston University.

CEO Compensation
  • Insufficient data for Ed to compare compensation growth.
  • Insufficient data for Ed to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Stoke Therapeutics management team in years:

1
Average Tenure
59
Average Age
  • The average tenure for the Stoke Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Ed Kaye

TITLE
CEO & Director
AGE
70
TENURE
1.8 yrs

Adrian Krainer

TITLE
Co-Founder & Director
AGE
60

Isabel Aznarez

TITLE
Co-Founder
AGE
47

Steve Tulipano

TITLE
Chief Financial Officer
AGE
60
TENURE
0.3 yrs

Huw Nash

TITLE
COO, Chief Business Officer & Secretary
AGE
52
TENURE
1.8 yrs

Gene Liau

TITLE
Executive VP
AGE
64
TENURE
1.5 yrs

Barry Ticho

TITLE
Chief Medical Officer
AGE
59
TENURE
1.8 yrs

Shamim Ruff

TITLE
Senior Vice President of Regulatory Affairs & Quality
AGE
59
TENURE
0.6 yrs

Nancy Wyant

TITLE
VP & Head of Clinical Operations
AGE
47
TENURE
0.6 yrs

Dawn Kalmar

TITLE
VP & Head of Corporate Affairs
AGE
42
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Stoke Therapeutics board of directors in years:

1.8
Average Tenure
59
Average Age
  • The average tenure for the Stoke Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Seth Harrison

TITLE
Chairman
AGE
59
TENURE
0.1 yrs

Ed Kaye

TITLE
CEO & Director
AGE
70
TENURE
1.8 yrs

Adrian Krainer

TITLE
Co-Founder & Director
AGE
60
TENURE
5.1 yrs

Arthur Tzianabos

TITLE
Director
AGE
56
TENURE
0.8 yrs

Jennifer Burstein

TITLE
Director
AGE
47
TENURE
0.1 yrs

Sam Hall

TITLE
Director

Art Levin

TITLE
Director
AGE
65
TENURE
3.8 yrs

Sam Hall

TITLE
Director
AGE
37
TENURE
4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
21. Jun 19 Buy Apple Tree Partners Company 21. Jun 19 21. Jun 19 1,388,889 $18.00 $25,000,002
20. Jun 19 Buy RTW Investments, LLC Company 19. Jun 19 19. Jun 19 555,556 $18.00 $10,000,008
X
Management checks
We assess Stoke Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Stoke Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

STOK News

Simply Wall St News

STOK Company Info

Description

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer epilepsy panel testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

Details
Name: Stoke Therapeutics, Inc.
STOK
Exchange: NasdaqGS
Founded: 2014
$765,515,494
32,644,584
Website: http://www.stoketherapeutics.com
Address: Stoke Therapeutics, Inc.
45 Wiggins Avenue,
Bedford,
Massachusetts, 01730,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS STOK Common Shares Nasdaq Global Select US USD 19. Jun 2019
BST 0GT Common Shares Boerse-Stuttgart DE EUR 19. Jun 2019
Number of employees
Current staff
Staff numbers
44
Stoke Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/22 03:34
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/15
Last earnings filing: 2019/05/23
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.